Dr. Sanjay Gupta

We work together, but I just so respect your reporting.

And I don't know if you realize this, but the last time we talked about GLP drugs was more than two years ago.

We talk about it all the time, yes.

We have a lot of conversations, Meg and I. But yeah, for the podcast, for our audience two years ago, and there's a lot that has changed since then, and I want to really focus on that.

But I'm just curious, overall, just the headline here.

I think it was 2017 or so when Ozempic hit the market.

How big a deal really are these GLP drugs now in the market?

Yeah.

You're talking about in terms of money spent on them?

Does this surprise you?

And I'll preface by saying you've been covering this for a long time, I think since the start, you know, here obviously, but also at CNBC.

When you first started reporting on this, could you have predicted where we would be in 2026?

No, no.

What was it that gave you pause?

The initial sort of thinking was that if you started these drugs, you're probably gonna be on them for your whole life.

And I think there was some data a couple of years ago when we were working on a documentary that showed that a pretty significant percentage of people were stopping these medications.

And it was either because of cost, side effects, or they sort of felt like it got them to where they wanted to be.

And now they were just going to use lifestyle changes to sort of maintain.

What are you seeing?

I mean, is there a way of contextualizing how long people stay on these medications or if they do stay on them for life?